Vertical Inhibition of RAS, RAF & MEK: Enhancing Antitumor Efficacy of KRAS G12C & G12D Inhibitors with RAF/MEK Clamp Avutometinib (Vs-6766)
Time: 1:45 pm
day: Day 2 Track A PM
Details:
- Examining how Avutometinib, a RAF/MEK clamp, has established clinical activity and safety with oral intermittent dosing, providing a promising new therapy
- Showcasing how combination with G12C inhibitors yields a deeper pERK blockade for enhanced tumor regression in G12C inhibitor-naïve and -resistant models, indicating potential for improved patient outcomes
- Understanding how combination with KRAS G12D inhibitors potentiates antitumor efficacy in colorectal and pancreatic cancer models, expanding the scope of therapy to more mutations and indications
